Trade on tv
NewsAI
positive
TechCrunch13m agoUSBUSINESS

Isomorphic Labs raises $5B as it looks to take drug candidates to clinical trials

1 min read8% importance258 words
T

TechCrunch

TechCrunch

Isomorphic Labs, the AI drug-discovery platform that was spun out of Google’s DeepMind in 2021, has raised $5 billion in a Series C funding round as it seeks to take its drug candidates to clinical trials.

The funding was co-led by Greenoaks and Sequoia Capital, with new investor Andreessen Horowitz and other investors also participating. All of the company’s existing backers, including Alphabet’s venture divisions GV and Capital G, Thrive Capital, MGX, Temasek, and the UK Sovereign AI Fund, also invested.

Isomorphic Labs builds an AI drug-design engine that uses a slew of simulation AI models that explore various areas of chemistry to help the company design drugs. The company, whose work builds on DeepMind’s breakthrough AlphaFold protein-folding AI model, said its program has yielded “positive preclinical results” in oncology and immunology. The lab has struck deals with pharma giants like Eli Lilly, Novartis, and Johnson & Johnson.

The new funding, which comes on the heels of a $2.1 billion Series B round in May, will be used to continue developing its drug-design engine, as well as to foray into more types of medicine.

The Series C is Isomorphic’s first fundraise since its founder and CEO, Demis Hassabis, left his position as head of DeepMind to focus on drug discovery, which also saw him moving into a chairman role at DeepMind. Hassabis and then-director of DeepMind John Jumper won the Nobel Prize in chemistry for the lab’s work on AlphaFold, a system that predicts the 3D structure of proteins with nothing more than their genetic sequence.

AI Summary

Isomorphic Labs, a Google DeepMind spin-off, raised $5 billion in Series C funding led by Greenoaks and Sequoia Capital. The company plans to use the capital to advance its AI-driven drug-design engine and move candidates into clinical trials.

Sentiment analysis

POSITIVEscore 0.80 · medium

    AI insights

    Newsworthiness8%
    Global impact8%
    Urgency

    low

    Freshness

    13m ago

    Audience

    general

    Follow-up

    Related categories
    TechnologyScienceHealthcare

    Financial analysis

    Relevance

    medium

    Market sensitivity

    medium

    Affected sectors

    business

    Affected assets

      Follow this story on TV

      Live charts and AI commentary on one screen with Trade on tv.

      Explore features